The HFC has developed a score integrating classes and doses of guideline-directed medical therapies prescribed for patients with heart failure (HF) and reduced ejection fraction. One potential use of this score is to test whether new treatments demonstrate incremental benefits, even in patients receiving comprehensive guideline-directed medical therapy.
Editors
Editor-in-Chief Christopher O’Connor, MD, FACC
Executive Editor Mona Fiuzat, PharmD, FACC
JACC Heart Failure CME Editors Tariq Ahmad, MD, MPH Adam DeVore, MDAbhinav Sharma, MDMitchell Psotka, MD, PhDKishan Parikh, MD
AuthorBrent C. Lampert, MD
Important Dates
Date of Release: July 25, 2022Term of Approval/Date of CME/MOC/ECME Expiration: July 24, 2023